Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
Status:
Withdrawn
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the as efficacy of rituximab as induction therapy in
membranous lupus nephritis. Safety and tolerability will additionally be assessed. Subjects
will receive open-label 2 courses of rituximab at baseline and at 6 months. They will be
followed monthly for 18 months to assess response and durability of response.
The hypothesis: B cell depletion will be an effective safe and well tolerated treatment for
membranous lupus nephritis (Class V).